natgillin/translations-raw huggingface dataset:
hepatit reaktivering af hepatitis B1) autoimmun hepatit1)
hepatitis reactivation of hepatitis B1)
hepatit reaktivering af hepatitis B1) autoimmun hepatit1)
hepatitis reactivation of hepatitis B1) autoimmune hepatitis1)
hepatit; genopblussen af hepatitis B;
hepatitis; reactivation of hepatitis B;
Hepatitis
Heptatitis
Hepatitis
Investigations
hepatitis (autoimmun hepatitis og lægemiddelinduceret leverskade)
hepatitis (autoimmune hepatitis and drug induced liver injury)
Hepatitis (inklusive
Hepatitis (including
hepatitis (inklusive forhøjet leverenzym)
hepatitis (including hepatic enzyme increased)
Hepatitis (inklusive hepatocellu lær kolestatisk eller blandet leverskade)
Hepatitis (including hepatocellular, cholestatic or mixed liver injury)11
Hepatitis (inklusive hepatocellul ær kolestatisk eller blandet leverskade)
Hepatitis (including hepatocellular, cholestatic or mixed liver injury)11
Hepatitis (inklusive hepatocellul ær kolestatisk eller blandet leverskade)11
Hepatitis (including hepatocellular, cholestatic or mixed liver injury)11
Hepatitis (inklusive hepatocellulær
Hepatitis (including
Hepatitis (inklusive hepatocellulær
Hepatitis (including hepatocellular,
Hepatitis (inklusive hepatocellulær
Hepatitis (including hepatocellular, cholestatic or mixed liver injury)11
Hepatitis (inklusive hepatocellulær cholestatisk eller blandet leverskade)11
Hepatitis (including hepatocellular, cholestatic or mixed liver injury) 11
Hepatitis (inklusive hepatocellulær kolestatisk eller blandet leverskade)
Hepatitis (including hepatocellular, cholestatic or mixed liver injury)11
Hepatitis (inklusive hepatocellulær kolestatisk eller blandet leverskade) 11
Hepatitis (including hepatocellula r, cholestatic or mixed liver injury)11
Hepatitis (inklusive hepatocellulær kolestatisk eller blandet leverskade)11
(including hepatocellular, cholestatic or mixed liver injury)11
Hepatitis (inklusive hepatocellulær kolestatisk eller blandet leverskade)11
Hepatitis (including hepatocellular, cholestatic or mixed liver injury) 11
Hepatitis (inklusive hepatocellulær kolestatisk eller blandet leverskade)11
hepatocellular, cholestatic or mixed liver injury)11
Hepatitis (inklusive hepatocellulær, kolestatisk eller blandet leverskade)11
Hepatitis (including hepatocellular, cholestatic or mixed liver injury)11
Hepatitis (inklusive øget AST, ALT, GGT), øget bilirubin i blodet (inklusive gulsot)
Hepatitis (including increased AST, ALT, GGT), blood bilirubin increased (including jaundice)
Hepatitis (leverbetændelse)
Hepatitis (inflamed liver)
hepatitis (leverbetændelse), gulsot (gulfarvning af hud eller øjne)
hepatitis (inflamation of the liver), jaundice (yellow of the skin or eyes)
Hepatitis A (inaktiveret) og hepatitis B (rDNA) (HAB)-vaccine (adsorberet).
Hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed).
Hepatitis A (inaktiveret)- og hepatitis B (rDNA) (HAB) -vaccine (adsorberet)
Hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed)
Hepatitis A (inaktiveret)- og hepatitis B (rDNA) (HAB) -vaccine (adsorberet).
Hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed).
Hepatitis A (inaktiveret)- og hepatitis B (rDNA) (HAB)-vaccine (adsorberet).
Hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed).
Hepatitis A- (inaktiveret) og hepatitis B (rDNA) (HAB)-vaccine (adsorberet)
Hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed).
Hepatitis A-virus (inaktiveret)1,2 360 ELISA enheder
Hepatitis A virus (inactivated)1,2 360 ELISA Units
Hepatitis A-virus (inaktiveret)1,2 720 ELISA enheder
Hepatitis A virus (inactivated)1,2 720 ELISA Units
Hepatitis A-virus (inaktiveret)1,2 720 ELISA units
Hepatitis A virus (inactivated) 1,2 720 ELISA Units
Hepatitis A-virus (inaktiveret)1,2 720 ELISA Units
Hepatitis A virus (inactivated)1,2 720 ELISA Units
Hepatitis A: Hepatitis A er en smitsom sygdom, der kan angribe leveren.
Hepatitis A: Hepatitis A is an infectious disease, which can affect the liver.
Hepatitis A: Hepatitis A er en smitsom sygdom, som kan angribe leveren.
Hepatitis A: Hepatitis A is an infectious disease, which can affect the liver.
Hepatitis A: Infektion med hepatitis A-virus kan medføre, at leveren svulmer op (en betændelsestilstand).
Hepatitis A: Infection with the hepatitis A virus may cause the liver to become swollen (inflamed).
Hepatitis Akut hepatitis Gulsot Levernekrose Hepatorenalt syndrom
Hepatitis Hepatitis acute Jaundice Hepatic necrosis Hepatorenal syndrome
hepatitis B (en virusforårsaget leverbetændelse)
hepatitis B (a viral liver infection);
Hepatitis B (rDNA)-vaccine (adjuveret, adsorberet)
Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed)
Hepatitis B (rDNA)-vaccine (adjuveret, adsorberet).
Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).
hepatitis B eller C og er i behandling med en kombination af antiretrovirale lægemidler, da du i så fald er i større risiko for at få en alvorlig og muligvis livstruende reaktion på grund af indvirkningen på leveren.
Hepatitis B or C and are being treated with a combination of antiretroviral agents, as you are at a greater risk of a severe and potentially life threatening reaction because of the effect on the liver.
Hepatitis B er et virus, som inficerer leveren og forårsager langvarig (kronisk) infektion, hvilket kan medføre leverskader.
Hepatitis B is a virus that infects the liver causes long term (chronic) infection,and can lead to liver damage.
Hepatitis B forårsages af hepatitis B virus.
Hepatitis B is caused by the hepatitis B virus.
Hepatitis B immunglobulin bør gives snarest muligt efter udsættelse (indenfor 24 timer).
Hepatitis B immunoglobulin should be given as soon as possible after exposure (within 24 hours).
Hepatitis B og/eller C
Hepatitis B and/or C
Hepatitis B overflade antigen (rDNA) 2, 3 10 µg
Hepatitis B surface antigen (rDNA) 2, 3 10 µg
Hepatitis B overflade antigen 1, 2, 3 20 mikrogram
Hepatitis B surface antigen 1, 2, 3 20 micrograms
Hepatitis B overflade antigen2,3 10 µg
Hepatitis B surface antigen2,3 10 µg
Hepatitis B overflade antigen2,3 10 μg
Hepatitis B surface antigen2,3 10 µg
Hepatitis B overflade-antigen, adsorberet, fremstillet i rekombinante gærceller (Saccharomyces cerevisiae) 5,0 µg
Adsorbed hepatitis B surface antigen produced in recombinant yeast cells 5.0 µg (Saccharomyces cerevisiae)
Hepatitis B overfladeantigen
Hepatitis B surface antigen
Hepatitis B overfladeantigen5 10 mikrogram
Hepatitis B surface antigen5 10 micrograms
Hepatitis B vaccine er blevet anerkendt som den første vaccine mod kræft fordi den kan forebygge primær leverkræft.
Hepatitis B vaccine has been recognized as the first anti-cancer vaccine because it can prevent primary liver cancer.
Hepatitis B virus overflade Antigen rekombinant** (S protein)*** 10 mikrogram
Hepatitis B virus surface Antigen recombinant** (S protein)*** 10 micrograms
Hepatitis B virus overflade-antigen, rekombinant (HBsAg) * ...............
Hepatitis B virus surface antigen, recombinant (HBsAg) * ...................
Hepatitis B virus overflade-antigen, rekombinant (HBsAg) * ...............
Hepatitis B virus surface antigen, recombinant (HBsAg) * ....................
Hepatitis B virus overflade-antigen, rekombinant (HBsAg) * ................
Hepatitis B virus surface antigen, recombinant (HBsAg) * ....................
Hepatitis B  er forårsaget af hepatitis B-virus.
Hepatitis B - is caused by the hepatitis B virus.
Hepatitis B- immunglobulin bør gives snarest muligt efter udsættelse (indenfor 24 timer).
Hepatitis B immunoglobulin should be given as soon as possible after exposure (within 24 hours).
Hepatitis B- infektion og - reaktivering
Hepatitis B infection and reactivation
Hepatitis B-immunglobulin påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene maskiner.
Hepatitis B immunoglobulin has no or negligible influence on the ability to drive and use machines.
Hepatitis B-infektion*, bronkopneumoni
Hepatitis B, Infection*, Bronchopneumonia
Hepatitis B-infektion*, bronkopneumoni
Tumour lysis syndrome
Hepatitis B-infektion, hvis du tidligere har haft hepatitis B
Hepatitis B infection when you have had hepatitis B in the past
Hepatitis B-overfladeantigen (HBs)2,3 10 mikrogram Poliovirus (inaktiveret) (IPV)
Hepatitis B surface antigen (HBs)2,3 10 micrograms Poliovirus (inactivated) (IPV)
Hepatitis B-overfladeantigen1, 2, 3 20 mikrogram
Hepatitis B surface antigen 1, 2, 3 20 micrograms
Hepatitis B-overfladeantigen1,2,3 20 mikrogram
Hepatitis B surface antigen 1, 2, 3 20 micrograms
Hepatitis B-overfladeantigen1,2,3 20 mikrogram
Hepatitis B surface antigen1, 2, 3 20 micrograms
Hepatitis B-overfladeantigen2,3 10 mikrogram
Hepatitis B surface antigen2,3 10 micrograms
Hepatitis B-overfladeantigen3,4 10 mikrogram
Hepatitis B surface antigen3,4 10 micrograms
Hepatitis B-overfladeantigen3,4 20 mikrogram
Hepatitis B surface antigen 3,4 20 micrograms
Hepatitis B-overfladeantigen3,4 20 mikrogram
Hepatitis B surface antigen3,4 20 micrograms
Hepatitis B-smittebærere har risiko for at få alvorlige leversygdomme, f.eks. cirrhose (skrumpelever) eller leverkræft.
Carriers of the virus are likely to get serious liver problems, such as “cirrhosis” or liver cancer.
Hepatitis B-vaccine (HBV)
Hepatitis B vaccine (HBV)
Hepatitis B-vaccine (rDNA)
Hepatitis B vaccine (rDNA)
Hepatitis B-virus
Hepatitis B virus
Hepatitis B-virus (HBV)
Hepatitis B virus (HBV)
Hepatitis B-virus (HBV) antivirale midler
Hepatitis B virus (HBV) antiviral agents
Hepatitis B-virus (HBV)-reaktivering og -infektion
Hepatitis B Virus (HBV) reactivation and infection
Hepatitis B-virus (HBV)-reaktivering og –infektion
Hepatitis B Virus (HBV) reactivation and infection
Hepatitis B-virus kan hos nogle mennesker forblive i kroppen hele livet igennem.
The hepatitis B virus stays in the body of some people all through their lives.
hepatitis B1
serious viral infection2
Hepatitis B: er forårsaget af hepatitis B-virus.
Hepatitis B: is caused by the hepatitis B virus.
Hepatitis B: Forårsages af hepatitis B-virussen.
Hepatitis B: caused by the hepatitis B virus.
Hepatitis B: Hepatitis B er forårsaget af hepatitis B-virus.
Hepatitis B: Hepatitis B is caused by the hepatitis B virus.
Hepatitis B: Hepatitis B forårsages af hepatitis B virus.
Hepatitis B: Hepatitis B is caused by the hepatitis B virus.
Hepatitis B: Hepatitis B forårsages af hepatitis B-virus.
Hepatitis B: Hepatitis B is caused by the hepatitis B virus.
Hepatitis B: Infektion med hepatitis B virus kan forårsage at leveren bliver opsvulmet (inflammeret).
Hepatitis B: Infection with the hepatitis B virus may cause the liver to become swollen (inflamed).
Hepatitis B: Infektion med hepatitis B-virus kan medføre, at leveren svulmer op (en betændelsestilstand).
Hepatitis B: Infection with the hepatitis B virus may cause the liver to become swollen (inflamed).
hepatitis C (N=22)
(0.95, 1.09)
hepatitis C (N=24)
substrate)
Hepatitis C antivirale lægemidler
Hepatitis C antivirals
hepatitis C-regimet (se
part of the hepatitis C
Hepatitis C: Fortæl det til lægen, hvis barnet har hepatitis C. Lægen kan ønske at overvåge behandlingen med Enbrel, i tilfælde af at infektionen forværres.
Hepatitis C: Tell your doctor if the child has hepatitis C. Your doctor may wish to monitor the treatment with Enbrel in case the infection worsens.
Hepatitis C: Fortæl det til lægen, hvis du eller barnet har hepatitis C. Lægen kan ønske at overvåge behandlingen med Enbrel, i tilfælde af at infektionen forværres.
Hepatitis C: Tell your doctor if you or the child have hepatitis C. Your doctor may wish to monitor the treatment with Enbrel in case the infection worsens.
Hepatitis C: Fortæl det til lægen, hvis du har hepatitis C. Lægen kan ønske at overvåge behandlingen med Benepali, i tilfælde af at infektionen forværres.
Hepatitis C: Tell your doctor if you have hepatitis C. Your doctor may wish to monitor the treatment with Benepali in case the infection worsens.
Hepatitis eksacerbationer efter seponering af behandling
Exacerbations of hepatitis after discontinuation of treatment
Hepatitis gik over hos 15 patienter.
Hepatitis resolved in 15 patients.
Hepatitis inklusive rapporter om leversvigt; pancreatitis
hepatitis, including reports of hepatic failure, pancreatitis.
hepatitis med eller uden gulsot
hepatitis with or without jaundice
Hepatitis medførte seponering af pembrolizumab hos 6 (0,2%) patienter.
Hepatitis led to discontinuation of pembrolizumab in 6 (0.2%) patients.
hepatitis*, cytolytisk hepatitis*
hepatitis*, cytolytic hepatitis
Hepatitis*, Hyperbilirubinæmi*
Hepatitis*, Hyperbilirubinaemia
Hepatitis, abnorm leverfunktion
Hepatitis, abnormal liver function
hepatitis, cholelithiasisa, kolestasea
hepatitis, cholelithiasisa, cholestasisa
hepatitis, cholestasis, cholecystitis
hepatitis, cholecystitis, cholestasis
hepatitis, cytolytisk hepatitis, hepatisk steatose, hepatomegali, forhøjet aminotransferase, forhøjet aspartat-aminotranferase, forhøjet bilirubin i blodet, forhøjet alkalisk fosfatase, forhøjet gamma- glutamyltransferase
acute renal failure, renal failure, nephrolithiasis, increased blood creatinine, proteinuria, bilirubinuria, dysuria, nocturia, pollakiuria
hepatitis, cytolytisk hepatitis, hepatisk steatose, hepatomegali, forhøjet aminotransferase, forhøjet aspartat-aminotranferase, forhøjet bilirubin i blodet, forhøjet alkalisk fosfatase, forhøjet gamma-glutamyltransferase
hepatitis, cytolytic hepatitis, hepatic steatosis, hepatomegaly, increased transaminase, increased aspartate aminotransferase, increased blood bilirubin, increased blood alkaline phosphatase, increased gamma-glutamyltransferase
Hepatitis, forhøjede leverfunktionstest
Hepatitis, elevated liver function tests
Hepatitis, gulsot, forhøjede leverenzymsværdier (mest i forbindelse med kolestase)
Hepatitis, jaundice, hepatic enzymes increased (mostly consistent with cholestasis)
hepatitis, gulsot, forhøjede leverenzymtal (ofte som følge af cholestase)
hepatitis, jaundice, hepatic enzyme elevations (mostly consistent with cholestasis)
Hepatitis, hepatocellulæ r skade, kolecystitis.
Hepatitis, hepatocellular damage, cholecystitis.
Hepatitis, icterus, hyperbilirubinæmi
Hepatitis, jaundice, hyperbilirubinaemia
Hepatitis, ikterus*, leverskader*
Hepatitis, jaundice*, liver injury
Hepatitis, leversteatose, alkoholisk hepatitis, leversvigt
hepatitis, hepatic steatosis, hepatitis alcoholic, hepatic failure
hepatitis, leversvigt, icterus
Hepatitis, hepatic failure jaundice
Hepatitis-eksacerbationer efter seponering af behandling
Exacerbations of hepatitis after discontinuation of treatment
Hepatitis-eksacerbationer: Spontane eksacerbationer ved kronisk hepatitis B er relativt hyppige og karakteriseres ved forbigående stigninger i serum-ALAT.
Exacerbations of hepatitis: spontaneous exacerbations in chronic hepatitis B are relatively common and are characterised by transient increases in serum ALT.
Hepatitis-patienter med levercirrose eller som for nylig er blevet behandlet med lægemidler, der påvirker immunsystemet,
hepatitis patients who have liver cirrhosis (scarring) that is causing symptoms or who have recently received medicines that affect the immune system,
Hepatitis/gulsot Leversvigt
Hepatitis/jaundice Hepatic failure
Hepatitis3
Dysuria Pollakiuria
hepatitis3, steatosis hepatis3
hepatitis3, hepatic steatosis3
Hepatitisa,am, gulsota,am, forhøjede leverenzymer (mest i forbindelse med kolestase)am
Hepatitisa,am, jaundicea,am, hepatic enzymes increased (mostly consistent with cholestasis)am
hepatitisb, hyperbilirubinæmi
hepatitisb, hyperbilirubinaemia
Hepatitiseksacerbationer er også beskrevet hos patienter, som har afsluttet behandling af hepatitis B. Forhøjede ALAT-niveauer efter afsluttet behandling er normalt forbundet med forhøjelser i serum- HBV-DNA-niveau, og hovedparten af disse tilfælde har vist sig at være selvbegrænsende.
Exacerbations of hepatitis have also been reported in patients who have terminated treatment of hepatitis B. Post-treatment ALT flares are normally associated with increases in serum HBV DNA levels, and the majority of such cases have proven to be self-limiting.
Hepatocellulær
disorde
Hepatocellulær
disorders
Hepatocellulær
Hepatobili
Hepatocellulær
Hepatocellu
hepatocellulær
hepatocellular,
hepatocellulær skade og hepatitis, kolestase og gulsot
hepatocellular damage and hepatitis, cholestasis and jaundice
hepatocellulær ødelæggelse, hepatitis, gulsot, hepatomegali,
hepatocellular damage, hepatitis, jaundice, hepatomegaly,
Hepatocellulære adenomer sås også i et 2- årigt carcinogenicitetsstudie med mus, som viste en let forøget forekomst i hanmus ved middel dosis og i både han- og hunmus ved den høje dosis.
The hepatocellular adenomas were also seen in a 2-year carcinogenicity study in mice, which demonstrated a small increased incidence of this finding in male mice at the mid dose, and in both male and female mice at the highest dose.
Hepatocellulære ændringer skal kontrolleres hyppigt hvis denne kombination anvendes.
Hepatocellular changes should be monitored frequently if this combination is prescribed.
hepatocellulært karcinom (11. april 2006)
hepatocellular carcinoma (11 April 2006)
hepatocellulært karcinom (en form for leverkræft)
hepatocellular carcinoma (a type of liver cancer);
Hepatocyt-degenerering og/eller -nekroser, der ofte er ledsaget af et øget niveau af serum- leverenzymer, blev observeret hos mus, rotter og hunde i doser, der forbindes med morbiditet og mortalitet eller som tåles dårligt.
Hepatocyte degeneration and/or necrosis, often accompanied by increased serum liver enzymes, was observed in mice, rats and dogs at doses that were associated with morbidity and mortality or were poorly tolerated.
Hepatoksicitet (herunder dødelig)٭
Hepatotoxicity (including fatalities)
Hepatomegali
Hepatomagaly
Hepatomegali Icterus
Hepatomegaly Jaundice
Hepatomegali Icterus
Rash Pruritis Alopecia
hepatopati (inklusive cirrhose), kolestase, øget indhold af bilirubin i blodet
hepatopathy (including cirrhosis), cholestasis, blood bilirubin increased
hepatosplenisk T-celle lymfom (en sjælden form for blodkræft, som ofte er dødelig);
hepatosplenic T-cell lymphoma (a rare blood cancer that is often fatal);
hepatosplenisk T-celle-lymfom (en sjælden form for blodkræft, som ofte er dødelig)
hepatosplenic T-cell lymphoma (a rare blood cancer that is often fatal)
Hepatosplenisk T-celle-lymfom (primæ rt hos unge og unge voksne med Crohns sygdom og colitis ulcerosa), Merkelcellekarcinom.
Hepatosplenic T-cell lymphoma (primarily in adolescents and young adults with Crohn’s disease and ulcerative colitis), Merkel cell carcinoma.
hepatosplenisk T-celle-lymfom,
hepatosplenic T-cell lymphoma1)
hepatosplenisk T-celle-lymfom1),
hepatosplenic T-cell lymphoma1)
hepatosplenomegali, cholecystitisa
hepatosplenomegaly, cholecystitisa
hepatosplenomegali, leverømhed, asterixis
liver tenderness, asterixis
Hepatotokisitet
Hepatotoxicity
Hepatotoksicitet (ALAT, ASAT)
Hepatic Toxicity (ALT, AST)
Hepatotoksicitet (herunder dødelig)٭
Hepatotoxicity (including fatalities)
Hepatotoksicitet (hovedsagelig beskrevet som forhøjede transaminaseniveauer)
Frequency not known: hepatotoxicity (mostly described as transaminase increased)
Hepatotoksicitet (inkl. leversygdom)
Eye disorders
Hepatotoksicitet (inkl. leversygdom)
Hepatotoxicity (inc liver disorder)
Hepatotoksicitet (inkl. leversygdom), hepatitis*, kolestase
Hepatotoxicity (inc liver disorder), Hepatitis*,
Hepatotoksicitet (inkl. leversygdom), hepatitis*, kolestase
Hepatotoxicity (inc liver disorder), Hepatitis*, Cholestasis
Hepatotoksicitet (inklusive letale tilfælde)
Hepatotoxicity, (including fatality)
hepatotoksicitet,
hepatotoxicity,
Hepatotoksicitet, (inklusive dødsfald)
Hepatotoxicity, (including fatality)
Hepatotoksicitet, (inklusive letale tilfælde)
Hepatotoxicity, (including fatality)
Hepatotoksicitetg
Hepatotoxicityg
Hepatoxicitet (herunder dødelig)٭
Hepatotoxicity (including fatalities)
Hepsera 10 mg tabletter leveres i flasker á 30 tabletter med silicagel som tørremiddel.
Hepsera 10 mg tablets are supplied in bottles of 30 tablets with silica gel desiccant.
Hepsera må ikke anvendes til børn eller unge under 18 år.
Do not use Hepsera in children or adolescents under 18 years of age.
Hepsera-tabletter skal tages en gang dagligt, oralt med eller uden mad.
Hepsera tablets should be taken once daily, orally with or without food.
Her blev 50 % (51 ud af 103) af de patienter, der fik Sovaldi og ribavirin i 12 uger, testet negative for hepatitis C, sammenholdt med 71 % (70 ud 98) af dem, der blev behandlet i 16 uger.
In this study, 50% (51 out of 103) of patients taking Sovaldi and ribavirin for 12 weeks tested negative for hepatitis C, whereas 71 % (70 out of 98) of patients treated for 16 weeks tested negative.
Her bør operationen om muligt udsættes til mindst 12 timer efter sidste dosis.
If possible, a surgery should be delayed until at least 12 hours after the last dose.
Her følger en oversigt over alle bivirkninger, som er set i kliniske studier: Almindelige:
The following is a list of side-effects observed in clinical trials: Common:
Her skal RebiDose injiceres
Where to inject with RebiDose
Her virker det som et fotosensibiliserende middel, dvs. et stof, der ændrer sig, når det udsættes for lys af en bestemt bølgelængde.
Reproduction is authorised provided the source is acknowledged. where it acts as a photosensitising agent (a substance that changes when exposed to light of a certain wavelength).
HER2 er en receptor for et kemisk signalstof kaldet epidermal vækstfaktor, som producerer signaler, der stimulerer kræftcellerne, så de ukontrolleret deler sig.
HER2 is a receptor for a chemical messenger called epidermal growth factor which produces signals that stimulate the cancer cells to divide uncontrollably.
HER2-negativ population
HER2-Negative Population
HER2-negative
HER2 Negative
HER2-positive
HER2 Positive
Heraf følger, at kontrollen af AUC efter intravenøs busulfan inden for det terapeutiske vindue ikke ændres, og der blev påvist samme target- performance med de to behandlingsplaner.
As a result, the control of intravenous busulfan AUC within the therapeutic windows is not modified and a similar targeting performance between the two schedules was illustrated.
Heraf har flere end 900 patienter været behandlet i et år eller længere.
Of these, 900 patients have been treated for one year or longer.
Heraf har flere end 900 patienter været behandlet i et år eller længere.
Of these, 900 patients patients have been treated for one year or longer.
Heraf har mere end 900 patienter været behandlet i et år eller længere.
Of these, 900 patients have been treated for one year or longer.
Heraf havde 185 (98,9 %) env-gener specifikke substitutioner i området af gp41 aminosyrerne 36-45.
185 (98.9%) env genes carried specific substitutions in region of aa 36 - 45 of gp41.
Heraf var den andel af patienter, som opnåede FTMH- lukning uden vitrektomi på dag 28, højere i Jetrea-gruppen end i placebogruppen (40,6 % vs.
Of these, the proportion of patients who achieved FTMH closure without vitrectomy at Day 28 was higher in the JETREA group than the placebo group (40.6% vs.
Herceptin 1 år N=1.693
Herceptin 1 Year
Herceptin 1 år N=1.702***
Herceptin 1 Year
Herceptin 150 mg pulver til infusionsvæske Trastuzumab
Herceptin 150 mg powder for infusion Trastuzumab
Herceptin 150 mg pulver til koncentrat til infusionsvæske, opløsning
Herceptin 150 mg powder for concentrate for solution for infusion
Herceptin 600 mg injektionsvæske, opløsning i hætteglas
Herceptin 600 mg solution for injection in vial
Herceptin 600 mg injektionsvæske, opløsning i hætteglas Trastuzumab
Herceptin 600 mg solution for injection Trastuzumab
Herceptin 600 mg injektionsvæske, opløsning i injektionssystem
Herceptin 600 mg solution for injection in administration system
Herceptin 600 mg injektionsvæske, opløsning i injektionssystem Trastuzumab
Herceptin 600 mg solution for injection in administration system Trastuzumab